After Needham and RBC Capital gave Boston Scientific Corp (NYSE: BSX) a Buy rating last month, the company received another Buy, this time from SunTrust Robinson. Analyst Bruce Nudell reiterated a Buy rating on Boston Scientific Corp yesterday and set a price target of $40. The company’s shares opened today at $35.
According to TipRanks.com, Nudell is a 4-star analyst with an average return of 9.4% and a 67.0% success rate. Nudell covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Edwards Lifesciences, and Nuvectra Corporation.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific Corp with a $37.94 average price target, which is an 8.4% upside from current levels. In a report issued on August 8, Canaccord Genuity also maintained a Buy rating on the stock with a $39 price target.
.
See today’s analyst top recommended stocks >>
Based on Boston Scientific Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.49 billion and net profit of $555 million. In comparison, last year the company earned revenue of $2.26 billion and had a net profit of $146 million.
Based on the recent corporate insider activity of 130 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
